Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
暂无分享,去创建一个
E. Novellino | F. Da Settimo | C. La Motta | Valeria La Pietra | S. Sartini | L. Botta | A. Antonelli | S. Ferrari | P. Fallahi | A. Moriconi | Vito Coviello | Luca Quattrini | Yi-Yu Ke | Hsieh Hsing-Pang | L. Marinelli
[1] M. Zabel,et al. Characterisation of thyroid medullary carcinoma TT cell line. , 1997, Histology and histopathology.
[2] R. Udelsman,et al. Management of thyroid cancer. , 2001, Annali italiani di chirurgia.
[3] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[4] Xin Chen,et al. Performance of Similarity Measures in 2D Fragment-Based Similarity Searching: Comparison of Structural Descriptors and Similarity Coefficients , 2002, J. Chem. Inf. Comput. Sci..
[5] A. Ryan,et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors , 2004, Oncogene.
[6] William Pao,et al. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Z. Werb,et al. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival , 2005, Nature Cell Biology.
[8] N. Meanwell,et al. A base-catalyzed, direct synthesis of 3,5-disubstituted 1,2,4-triazoles from nitriles and hydrazides , 2005 .
[9] Svend Kjær,et al. Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.
[10] C. Strock,et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.
[11] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[12] Sanjivanjit K. Bhal,et al. The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. , 2007, Molecular pharmaceutics.
[13] Jürgen Bajorath,et al. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. , 2007, Drug discovery today.
[14] G. G. Dubinina,et al. In silico design of protein kinase inhibitors: successes and failures. , 2007, Anti-cancer agents in medicinal chemistry.
[15] P. Miccoli,et al. Dedifferentiated thyroid cancer: a therapeutic challenge. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[16] S. Moore. Molecular targets in medullary thyroid carcinoma , 2008 .
[17] M. Yeh,et al. Inherited endocrinopathies: an update. , 2008, Molecular genetics and metabolism.
[18] A. Pinchera,et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.
[19] George Karypis,et al. Indirect Similarity Based Methods for Effective Scaffold-Hopping in Chemical Compounds , 2008, J. Chem. Inf. Model..
[20] E. Ferrannini,et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. , 2008, European journal of endocrinology.
[21] E. Ferrannini,et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine‐needle aspiration used for chemosensitivity tests , 2008, Clinical endocrinology.
[22] Giampietro Gasparini,et al. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications , 2008, Nature Clinical Practice Oncology.
[23] F. Zunino,et al. Targeting RET for thyroid cancer therapy. , 2009, Biochemical pharmacology.
[24] Gennady Verkhivker,et al. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. , 2009, Biophysical journal.
[25] F. Da Settimo,et al. Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. , 2009, Journal of medicinal chemistry.
[26] M. Shah,et al. Targeting RET Receptor Tyrosine Kinase Activation in Cancer , 2010, Clinical Cancer Research.
[27] J. Murray-Rust,et al. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. , 2010, Bioorganic & medicinal chemistry.
[28] M. Pelizzo,et al. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT , 2011, BMC Cancer.
[29] G. Alí,et al. Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer , 2011 .
[30] Raimund Mannhold,et al. QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability. , 2012, Molecular pharmaceutics.
[31] N. Chau,et al. Vandetanib for the Treatment of Medullary Thyroid Cancer , 2012, Clinical Cancer Research.
[32] M. Sugawara,et al. Medullary Thyroid Cancer—Current Treatment Strategy, Novel Therapies and Perspectives for the Future , 2012, Hormones and Cancer.
[33] F. Kraeber-Bodéré,et al. Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Novellino,et al. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. , 2012, Journal of medicinal chemistry.
[35] E. Kebebew,et al. Diagnosis of thyroid cancer: state of art. , 2013, Expert opinion on medical diagnostics.
[36] E. Novellino,et al. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. , 2013, Journal of medicinal chemistry.
[37] Alessandro Antonelli,et al. Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma , 2013, International journal of endocrinology.
[38] M. Borrello,et al. RET inhibition: implications in cancer therapy , 2013, Expert opinion on therapeutic targets.
[39] F. Da Settimo,et al. Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). , 2013, European journal of medicinal chemistry.
[40] M. Kreissl,et al. Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Erin F. Simonds,et al. Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.
[42] E. Novellino,et al. Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies. , 2014, Journal of medicinal chemistry.
[43] Johannes C. Hermann,et al. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines. , 2014, Bioorganic & medicinal chemistry letters.
[44] Nathan Brown,et al. Best of Both Worlds: On the Complementarity of Ligand-Based and Structure-Based Virtual Screening , 2014, J. Chem. Inf. Model..
[45] Weilin Wu,et al. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. , 2015, Journal of medicinal chemistry.
[46] J. Edwards,et al. A Prospective Virtual Screening Study: Enriching Hit Rates and Designing Focus Libraries To Find Inhibitors of PI3Kδ and PI3Kγ. , 2016, Journal of medicinal chemistry.
[47] C. La Motta,et al. Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells , 2017, Medicinal research reviews.